June 24, 2020 / 3:38 PM / 12 days ago

Drug pricing review group raises recommended price for Gilead's remdesivir

June 24 (Reuters) - The Institute for Clinical and Economic Review on Wednesday boosted its benchmark price for Gilead Sciences Inc’s remdesivir, suggesting the antiviral could be priced up to $5,080, based on benefits shown in COVID-19 patients.

The Boston-based group had previously suggested a price of around $4,500 for a 10-day course of remdesivir. Gilead has not announced the price of the therapy in the United States. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below